The US FDA committee votes in favour of the favourable benefit-risk profile of Paxlovid from Pfizer’s.

The US FDA committee votes in favour of the favourable benefit-risk profile of Paxlovid from Pfizer’s.

According to a report from Pfizer Inc., the Antimicrobial Drugs Advisory Committee (AMDAC) of the US Food and Drug Administration (FDA) voted 16 to 1 in favour of the safety and efficacy of Paxlovid (nirmatrelvir and ritonavir tablets) for the…